Cellular Biomedicine has begun to enroll patients in China for its Phase I clinical trial to assess the safety and efficacy of C-CAR088, its anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for patients with relapsed or refractory multiple myeloma.
Enrollment initiated for Phase I anti-BCMA CAR T-cell therapy trial
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.